The Drug Class Everyone Left for Dead Just Got a Pulse
AstraZeneca's tozorakimab just nailed two Phase 3 trials in COPD, a disease that has been a graveyard for biologic drugs. The kicker? It worked across the board, not just in narrow patient subsets, potentially unlocking a $5 billion opportunity in a market everyone left for dead.
For the last few years, trying to build a biologic drug for COPD has felt a lot like trying to open a restaurant in a cursed location. One after another, big pharma companies walked in with promising ideas and walked out with "CLOSED" signs. Benralizumab? Failed. Tezepelumab? Missed. Itepekimab? Split decision at best.
So when AstraZeneca stepped up to the plate with yet another antibody for COPD, the market collectively shrugged. Guggenheim Securities reportedly had "appropriately low" expectations for the program. Analysts weren't exactly popping champagne in advance.
Then the data dropped on March 27, 2026.
What happened? Tozorakimab, AstraZeneca's anti-IL-33 antibody, hit its primary endpoint in not one but two Phase 3 trials. The drug significantly reduced flare-ups (called exacerbations) in patients with moderate-to-severe COPD, added on top of standard inhaler therapy. That might sound like another press release. But in context, it's closer to a resurrection.
The Graveyard That Came Before
To understand why this matters, you need to know how brutal the COPD biologics space has been.
COPD (chronic obstructive pulmonary disease) affects hundreds of millions of people worldwide. It's a massive, devastating disease where the lungs slowly lose their ability to move air. Standard treatments, mostly inhalers containing bronchodilators and steroids, help but don't solve the problem. Patients still end up in the hospital with dangerous flare-ups that accelerate lung damage.
Biologics, the antibody-based drugs that revolutionized asthma treatment, seemed like the obvious next step. The logic was simple: if you can calm the immune system's overreaction in asthma, maybe you can do the same in COPD.
The logic was wrong. Or at least, it was incomplete.
AstraZeneca's own benralizumab (brand name Fasenra) failed two major Phase 3 trials called GALATHEA and TERRANOVA, enrolling over 2,500 patients. The drug wiped out a specific immune cell called eosinophils, but exacerbation rates barely budged. Tezepelumab, which blocks a protein called TSLP, posted a Phase 2 miss in 2024 with a p-value of 0.10 (in clinical trials, you generally need below 0.05 to claim success). Roche's astegolimab, another IL-33 blocker, looked promising in Phase 2b but flopped in Phase 3.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Even Sanofi and Regeneron's itepekimab, which targets the same protein as tozorakimab (IL-33), delivered a split verdict: one Phase 3 trial hit, one missed. That's like going 1-for-2 in a best-of-two series. You don't advance.
The only bright spot was Dupixent (dupilumab), which succeeded in two Phase 3 trials. But Dupixent only works in patients with high eosinophil counts, roughly 20-40% of the moderate-to-severe population. It cracked open a door, not the whole wall.
Why Tozorakimab Is Different (Maybe)
So what makes AstraZeneca's latest attempt special? Three things stand out.
First, it worked broadly. The two trials, called OBERON and TITANIA, enrolled former smokers as the primary population. But the efficacy held up consistently across the overall group: current smokers, patients with low eosinophil counts, patients with high eosinophil counts, and patients at all stages of lung function severity. That's a huge deal. Most COPD biologics only show a signal in narrow slices of the patient population. Tozorakimab appears to work across the board.
Second, the mechanism is more comprehensive. This is where the science gets interesting. IL-33 is an "alarm" protein that the body releases when lung tissue is damaged. It triggers inflammation through a receptor called ST2. But IL-33 also signals through a completely different set of receptors (RAGE and EGFR) that drive mucus production and tissue remodeling, two hallmarks of COPD that pure inflammation-blockers miss.
Think of it like a house fire. Previous drugs were essentially turning off the smoke alarm (blocking one signal) while the fire kept burning through a back door. Tozorakimab blocks both the ST2 pathway and the RAGE/EGFR pathway simultaneously. It shuts down IL-33 in both its reduced and oxidized forms, covering the front door and the back.
Competitors like itepekimab and astegolimab didn't achieve this dual blockade, which may be a possible explanation for the divergent results.
Third, timing may have helped. TD Cowen analysts pointed out that AstraZeneca's trials enrolled patients during the post-COVID period, when baseline exacerbation rates were likely higher. More frequent flare-ups in the placebo group make it easier to demonstrate a treatment benefit. It's a legitimate scientific nuance, not a flaw, but it's worth noting.
A $5 Billion Question
The financial implications are enormous. AstraZeneca projects peak sales of $3 billion to $5 billion for tozorakimab. To put that in perspective, the entire global COPD biologics market was worth about $605 million in 2024. If tozorakimab hits those projections, it wouldn't just dominate the category; it would expand it by an order of magnitude.
Why such a big number? Because unlike Dupixent, which is limited to eosinophilic patients, tozorakimab's broad efficacy means it could theoretically be prescribed to a much larger share of COPD patients. GlobalData analyst Vinie Varkey highlighted this, noting that the drug's activity across all eosinophil levels gives it a fundamentally wider addressable market.
The broader COPD therapeutics market is projected to reach approximately $22.9 billion by 2026, growing at roughly 5.4% annually. Biologics are the fastest-growing segment within that, expanding at a 12.1% clip. A drug that works broadly in COPD isn't just entering a market; it's potentially creating one.
The Caveats (Because There Are Always Caveats)
Before anyone gets too excited, some important asterisks.
AstraZeneca released topline results only. That means we know the trials hit their primary endpoint, but we don't have the actual numbers yet. No specific percentage reduction in exacerbations. No detailed safety breakdown. No subgroup analyses. Full data will be presented at an upcoming medical meeting, and the devil, as always, lives in those details.
The safety profile was described as "favorable" with "good tolerability," which is encouraging but vague. Biologics can carry risks like injection site reactions, immunogenicity (the body making antibodies against the drug), and infections. We'll need the full dataset to evaluate the risk-benefit properly.
There are also two more Phase 3 trials running: PROSPERO (an open-label extension of OBERON and TITANIA) and MIRANDA, both expected to report in 2026. Consistency across all four trials would cement the story. Inconsistency would reopen every doubt.
What This Means for the COPD Landscape
If tozorakimab's full data hold up, the implications ripple outward.
For patients, this could mean the first biologic that works regardless of their eosinophil count or smoking status. That's millions of people currently stuck on inhalers with no next-line option when things get worse.
For Sanofi and Regeneron, the pressure just intensified. Itepekimab's mixed Phase 3 results now look even more problematic by comparison. The companies are reportedly exploring regulatory paths forward, but a clean win from a competitor makes that conversation harder.
For AstraZeneca, this validates a respiratory strategy that has weathered some painful setbacks. The same company that failed with benralizumab in COPD may now have the biggest biologic opportunity in the disease. Sometimes you have to lose with the wrong key before you find the right one.
And for the broader field, it revives the hypothesis that COPD can be treated with precision biologics; you just have to pick the right target and block it completely. IL-33 might be the master switch that upstream targets like IL-5 and TSLP never were.
The Bottom Line
COPD biologics have been a story of expensive failures and narrowing ambitions. Dupixent proved you could succeed if you picked the right patients. Tozorakimab is now suggesting you might not have to pick at all.
Two positive Phase 3 trials. Broad efficacy. A mechanism that addresses inflammation and mucus production simultaneously. Peak sales projections that would dwarf the current market.
It's early, and the full data still need to deliver. But for a drug class that everyone had written off, March 27 felt a lot like a comeback story worth watching.
Clinical & Regulatory
4 min read
One Shot to Replace Seven: The Insulin Revolution Is Here
The FDA just approved the first-ever weekly insulin, cutting injections from 365 to 52 per year. For millions of diabetes patients who forget, skip, or dread their daily shots, Novo Nordisk's Awiqli could be the biggest convenience leap in insulin's 100-year history.
